(Companies Covered: Cadila Pharmaceuticals, Dr. Reddy`s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon)
The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate of -12.93%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $751.96 billion in 2023 at a compound annual growth rate of 19.11%.
Read More On The Global Filgrastim Biosimilars Market Report At –
The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. Only goods and services traded between entities or sold to end consumers are included.
Global Filgrastim Biosimilars Market Segmentation –
1) By Application: Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Others.
2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.
Global Filgrastim Biosimilars Market Driver –
Companies in the filgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other and with academic and research institutions in this market by way of partnerships, in- or out-licensing deals, this trend has been increasing over recent years.
Request For A Sample Of The Global Filgrastim Biosimilars Market Report At –
https://www.thebusinessresearchcompany.com/sample.aspx?id=3426&type=smp
Few Points From The Global Filgrastim Biosimilars Market TOC
1. Executive Summary
2. Filgrastim Biosimilars Market Characteristics
3. Filgrastim Biosimilars Market Size And Growth
3.1. Global Filgrastim Biosimilars Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Filgrastim Biosimilars Forecast Market, 2019 – 2023F, 2025F, 2030F, $ Billion
4. Filgrastim Biosimilars Market Segmentation
4.1. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Filgrastim Biosimilars Market Regional And Country Analysis
5.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.1. Asia-Pacific Filgrastim Biosimilars Market Overview
6.2. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
Media Contact
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
Address:
City: London
State: Greater London
Country: United Kingdom
Website: https://www.thebusinessresearchcompany.com/